Cargando…
Adnectins: engineered target-binding protein therapeutics
Adnectins(TM) are a new family of therapeutic proteins based on the 10th fibronectin type III domain, and designed to bind with high affinity and specificity to therapeutically relevant targets. Adnectins share with antibody variable domains a beta-sheet sandwich fold with diversified loops, but dif...
Autor principal: | Lipovšek, D. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3003446/ https://www.ncbi.nlm.nih.gov/pubmed/21068165 http://dx.doi.org/10.1093/protein/gzq097 |
Ejemplares similares
-
Adnectin–drug conjugates for Glypican-3-specific delivery of a cytotoxic payload to tumors
por: Lipovšek, Daša, et al.
Publicado: (2018) -
Enhancing bioactivity, physicochemical, and pharmacokinetic properties of a nano-sized, anti-VEGFR2 Adnectin, through PASylation technology
por: Aghaabdollahian, Safieh, et al.
Publicado: (2019) -
The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer
por: Dineen, Sean P, et al.
Publicado: (2008) -
RNA-binding proteins as targets for pain therapeutics
por: de la Peña, June Bryan, et al.
Publicado: (2018) -
Non-antibody Approaches to Proprotein Convertase Subtilisin Kexin 9 Inhibition: siRNA, Antisense Oligonucleotides, Adnectins, Vaccination, and New Attempts at Small-Molecule Inhibitors Based on New Discoveries
por: Nishikido, Toshiyuki, et al.
Publicado: (2019)